new york, new york • the waldorf=astoria - imedex, llc · the new york presbyterian hospital new...
TRANSCRIPT
P r o g r a m C h a i r sC h a i r
Morton Coleman, MDCenter for Lymphoma and Myeloma
Weill Cornell Medical College The New York Presbyterian Hospital
New York, New York
C o - C h a i r, L y m p h o m a S e s s i o nJohn P. Leonard, MD
Center for Lymphoma and Myeloma Weill Cornell Medical College
The New York Presbyterian Hospital New York, New York
C o - C h a i r, My e l o m a S e s s i o nRuben Niesvizky, MD
Center for Lymphoma and Myeloma Weill Cornell Medical College
The New York Presbyterian Hospital New York, New York
C o - C h a i r, L e u k e m i a S e s s i o nRichard R. Furman, MD
Center for Lymphoma and Myeloma Weill Cornell Medical College
The New York Presbyterian Hospital New York, New York
W W W . I M E D E X . C O M
October 22-24, 2009 I New York, New York The Waldorf=Astoria
2nd Announcement
October 16-18, 2008 • New York, New York • The Waldorf=Astoria
A comprehensive forum presenting the most recent developments in lymphocytic and plasma cell neoplasms
D ear C o l l e a g u e ,It is our pleasure to invite you to join us at Lymphoma & Myeloma 2009: An International Congress on Hematologic Malignancies. This fall’s Congress, October 22-24, 2009 at The Waldorf=Astoria in New York, New York, promises to be our most exciting and interactive meeting yet!
Since its inception in 2000, this Congress has grown to nearly 800 attendees and has become the premier forum for discussion on the latest advances in lymphoma and myeloma. Using a dynamic approach, featuring clinical controversies, debates, and examinations of current treatment regimens, attendees will receive a thorough understanding of the evolution of thought and therapy of lymphoma and myeloma, as well as any significant developments which may lead to improved results.
Guided by the expertise of the leaders in the fields of molecular biology, pathology, immunology, and translational and clinical research, this Congress will provide for a stimulating and interactive forum for attendees from all relevant medical specialties.
Allowing attendees the benefit of visiting New York City during one of the most beautiful times of year, this Congress will be the perfect chance for you to get away and enjoy a weekend of learning in the capital city of the world.
We cordially welcome you to our fair city and promise to reward you with an exciting, informative Congress!
Sincerely,
Morton Coleman, MD, Chair
John P. Leonard, MD, Co-Chair, Lymphoma Session
Ruben Niesvizky, MD, Co-Chair, Myeloma Session
Richard R. Furman, MD, Co-Chair, Leukemia Session
October 22-24, 2009 I New York, New York I The Waldorf=Astoria
C o n g re s s O rg a n i z e r
Dark Blue C100, M55, Y0, K55
Light Blue C29, M12, Y0, K0
Orange C0, M66, Y100, K0
4325 Alexander Drive Alpharetta, Georgia 30022-3740, USA Tel.: +1 (770) 751 7332 Fax: +1 (770) 751 7334 Email: [email protected] www.imedex.com
• DiscussinsightsintothebiologyofCLL
• Discussevidenced-basedapproachestotherapy in CLL in both the frontline and relapsed setting
• Reviewexperimentalandrecentlyapproved agents in CLL
• Reviewthemostuptodateclinicaltrialdata in lymphoplasmocytic disorders
• DiscussthenewWHOclassification of lymphoma
• Commentontheevolutionandfutureoftreatment for Hodgkin’s disease
• Reviewtheoptimalfrontlinestrategyforpatients with peripheral T cell lymphoma
• Discussprogressmadeincutaneous T cell lymphoma
• Debatetheaggressivetreatmentofmantlecell lymphoma
• Improvepreventionandtreatmentofcentral nervous system lymphoma
• Commentontheroleofepigenetictargeting of large cell lymphoma
• Utilizeprognosticfactorstooptimizetreatment of low grade lymphoma
• Reviewtreatmentoflymphomasoftheeye
• Discussutilityandsafetyofnovelagentsinlow grade lymphoma
• DebatetheroleofPETscansinHodgkin’sand NHL
• Reviewupdatesinmyelomabiology,includingcelltrafficking,mobilizationandtargeting the cell cycle
• Reviewtheevaluationofminimalresidualdisease in myeloma as well as the IMW consensus on response criteria
• Discussthecurrentstateoftheartintargeted therapy for myeloma
• Reviewevidence-basedtreatmentoptionsfor poor risk and non-transplant eligible patients in the frontline
• Discussevidence-basedtreatmentoptionsfor consolidation in patients with good prognostic indicators
• Reviewnovelcombination therapies for the treatment of relapsed/refractory myeloma
• Reviewhighlightsfromthe2009International Myeloma Workshop
C o n t i n u i n g M e d i c a l E d u ca t i o nCME Statement
Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to
provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum 18.5 of AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
W h o S h o u l d A tte n dThis educational activity is specifically designed for hematologists, medical oncologists, transplant oncologists, radiation oncologists and other physicians, physicians-in-training, and healthcare professionals (nurses, pharmacists) involved and/or interested in lymphoma, myeloma and related plasma cell disorders and their management.
O b j e c t i v e sAfter attending this Congress, participants should be able to:
James R. Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, California
Steven Bernstein, MD University of Rochester Medical Center Rochester, New York
Joan Bladé, MD University of Barcelona Hospital Clinic Barcelona, Spain
Arthur R. Bradwell, MD University of Birmingham Birmingham, United Kingdom
John C. Byrd, MD Ohio State University Columbus, Ohio
Asher Chanan-Khan, MD Roswell Park Cancer Institute Buffalo, New York
Selina Chen-Kiang, PhD Weill Medical College of Cornell University New York, New York
Bruce D. Cheson, MD Georgetown University Hospital Washington, District of Columbia
Bertrand Coiffier, MD Hospices Civils de Lyon Lyon, France
Morton, Coleman, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Raymond L. Comenzo, MD Tufts University Medical Center Boston, Massachusetts
Claire Dearden, BSc, M.D., FRCP, FPCPathRoyal Marsden Hospital Sutton, United Kingdom
Volker Diehl, MD University Hospital of Cologne Cologne, Germany
Angela Dispenzieri, MD Mayo Clinic College of Medicine Rochester, Minnesota
Rebecca Elstrom, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Scott Ely, MD, MPH Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Rafael Fonseca, MD Mayo Clinic Scottsdale,Arizona
Richard R. Furman, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Randy D. Gascoyne, MD British Columbia Cancer Agency Vancouver, British Columbia, Canada
Philip R. Greipp, MD Mayo Clinic Rochester, Minnesota
Thomas Habermann, MD Mayo Clinic Rochester, Minnesota
Jean-Luc Harousseau, MD Hoteldieu Hospital Nantes, France
Sandra J. Horning, MD Stanford University Medical Center Stanford, California
Steven Horwitz, MD Memorial Sloan-Kettering Cancer Center New York, New York
Carol Ann Huff, MDJohns Hopkins University Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland
Martin Hutchings, MD Copenhagen University Hospital Copenhagen, Denmark
Sundar Jagannath, MD St. Vincent’s Comprehensive Cancer Center New York, New York
Brad Kahl, MD University of Wisconsin Carbone Comprehensive Cancer Center Madison, Wisconsin
Neil Kaye, MD Mayo Clinic Rochester, Minnesota
Eva Kimby, MD, PhD Karolinska Institute at Huddinge University Hospital Stockholm, Sweden
Suzanne Lentzsch, MD, PhD University of Pittsburgh Medical Center Pittsburgh, Pennsylvania
John P. Leonard, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Sagar Lonial, MD Emory University Atlanta, Georgia
Tomer Mark, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Peter Martin, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Peter McLaughlin, MD University of Texas M. D. Anderson Cancer Center Houston, Texas
Fa c u lt y
October 22-24, 2009 I New York, New York I The Waldorf=Astoria
C o rp o ra te S u p p o rtThe following companies have provided an educational grant in support of this Congress:
Ari Melnick, MD Albert Einstein College of Medicine Bronx, New York
Ruben Niesvizky, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Antonio Palumbo, MD University of Torino Torino, Italy
Roger Pearse, MD Center for Lymphoma and Myeloma Weill Cornell Medical College The New York Presbyterian Hospital New York, New York
Kanti Rai, MD Long Island Jewish Medical Center Albert Einstein College of Medicine New Hyde Park, New York
S. Vincent Rajkumar, MD Mayo Clinic Rochester, Minnesota
Steven Rosen, MD Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois
Stephen Schuster, MD University of Pennsylvania Philadelphia, Pennsylvania
Keith Stewart, M.B.Ch.B Mayo Clinic Scottsdale,Arizona
Wayne Tam, MD, PhD Weill Cornell Medical Center New York, New York
David J. Wolf, MD Weill Cornell Medical College New York, New York
Platinum
Genentech BioOncology and Biogen Idec
Millennium Pharmaceuticals, Inc.
Silver
Corporate
Awards Support
E x h i b i t o rThe following companies are exhibitors at this Congress:
Lippincott Williams
& Wilkins
Several options are available to companies interested in supporting this Congress. For more information, please contact Imedex at +1 (770) 751 7332 or by email at [email protected].
8:00 am Welcome Morton Coleman, MD
CLL Section
8:05 am Introduction Richard R. Furman, MD Session I: Biology of CLL Moderator: John C. Byrd, MD
8:10 am New insights into CLL biology Speaker invited
8:30 am CLL genomics and epigenetics: What’sonthehorizonforclinicians? John C. Byrd, MD
8:50 am How do we make sense of prognostic markers in CLL when treatingpatients? Kanti Rai, MD
9:10 am Panel discussion questions
9:30 am Break Session II: Treatment of CLL Moderator: Richard Furman, MD
9:50 am Evidence-based approaches for treatment-naïve patients Neil Kaye, MD
10:10 am Evidence-based approaches for treating relapsed/ refractory patients Claire Dearden, BSc, MD, FRCP, FPCPath
10:30 am Latest results with IMiDS compounds in CLL: How do we managetherashandflare? Asher Chanan-Khan, MD
10:50 am Experimental and recently approved novel agents in CLL Richard R. Furman, MD
11:10 am Panel discussion
11:20 am Presentation of the best CLL abstract
11:30 am Luncheon Symposium
Session III: Lymphoplasmocytic disorders Moderator: David J. Wolf, MD
1:30 pm Waldenstrom’s macroglobulinemia: An update Eva Kimby, MD, PhD
1:50 pm POEMS and Castleman’s disease: Is therearolefornovelagents? Angela Dispenzieri, MD
2:10 pm Amyloidosis: Recent data Raymond L. Comenzo, MD
2:30 pm Break
Lyphoma Section
2:50 pm Introduction John P. Leonard, MD Session IV: Biology of lymphoma Moderator: Wayne Tam, MD, PhD
2:55 pm The biologic and pathologic basis for the new WHO classification Randy D. Gascoyne, MD
3:15 pm A clinician’s view of the new WHO classification Speaker invited
3:35 pm Panel discussion
3:45 pm Presentation of the best Lymphoma abstract
3:55 pm The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: John Ultmann Award for Contributions to Lymphoma Research
Recipient: Volker Diehl, MD
Presenter: Speaker invited
4:05 pm Hodgkin’s disease: The past, the present and the future Volker Diehl, MD
4:35 pm Questions and answers
4:45 pm Adjourn
S c i e n t i f i c A g e n daThursday, October 22, 2009
Friday, October 23, 2009
8:00 am Welcome Morton Coleman, MD
8:05 am Introduction John P. Leonard, MD Session V: T cell lymphoma Moderator: Rebecca Elstrom, MD
8:10 am What is the best front line strategy for peripheral T-cell lymphoma: Is there a role of novel agentsandtransplantation? Steven Horwitz, MD
8:30 am Have we made progress in the systemic therapy of treating cutaneousT-celllymphoma? Steven Rosen, MD
8:50 am Angioimmunoblastic lymphadenopathy: What is latestinbiologyandtreatment? Rebecca Elstrom, MD
9:10 am Panel discussion and questions
9:20 am Break Session VI: Mantle cell lymphoma Moderator: John P. Leonard, MD
9:40 am Debate: Should mantle cell lymphoma be treated aggressively fromtheonset?
Pro: Brad Kahl, MD Con: Peter Martin, MD
Moderator: John P. Leonard, MD
10:20 am Discussion and questions Session VII: Special concerns in large cell lymphomaModerator: Thomas Habermann, MD
10:30 am What is the best treat for low stageaggressivelymphomas? Thomas Habermann, MD
10:50 am How to prevent and treatment central nervous system disease Steven Bernstein, MD
11:10 am How can we improve on large cell lymphomatreatment? Bertrand Coiffier, MD
11:30 am Genomic/epigenetic targeting of large cell lymphoma: Does it haveclinicalapplication? Ari Melnick, MD
11:50 am Discussion and questions
12:00 pm Luncheon Symposium Session VIII: Low grade lymphoma Moderator: Peter McLaughlin, MD
2:00pm Isfollicularlymphomacurable? If not, has it become a chronicillness? Peter McLaughlin, MD
2:20 pm Strategies for low grade lymphoma: How to use prognostic indicators in treatment John P. Leonard, MD
2:40 pm Lymphomas of the eye: MALT, follicular, large cell Morton Coleman, MD
3:00 pm Novel agents in low grade lymphoma: More than we canhandle? Bruce D. Cheson, MD
3:20 pm Vaccines redux: Useless oraphoenix? Stephen Schuster, MD
3:40 pm Break Session IX: Hodgkin’s disease: PET scanning Moderator: Morton Coleman, MD
4:00 pm Point – Counterpoint: PET scans in Hodgkin’s and non-Hodgkin’s lymphoma
The new promise of PET scans Martin Hutchings, MD
The new peril of PET scans Sandra J. Horning, MD
Moderator: Morton Coleman, MD
4:30 pm Discussion and questions
4:45 pm Adjourn
Saturday, October 24, 2009
S c i e n t i f i c A g e n da continued
Myeloma Section
8:05 am Introduction Ruben Niesvizky, MD Session X: Biology of myeloma Moderator: Scott Ely, MD, MPH
8:10 am Chromosomes, genomics and proteomics as a disease primer: IsM-SMARTsmart? Rafael Fonseca, MD
8:30 am Myeloma cell trafficking andmobilization Speaker invited
8:50 am Debate: Does the myeloma stem cellexist?Canwetargetitfor therapeuticpurposes? Suzanne Lentzsch, MD, PhD Carol Ann Huff, MD
9:20 am Targeting the cell cycle in myeloma and lymphoma Selina Chen- Kiang, PhD
9:40 am Discussion and questions Session XI: Clinical pathology and myeloma Moderator: Tomer Mark, MD
9:50 am Measurement of free light and heavychains:Applications? Arthur R. Bradwell, MD
10:05 am Minimal residual disease in myeloma: Flow cytometry and molecular techniques: IsMRDclinicallyrelevant? Speaker invited
10:25 am The Tower of Babel: Multiple response criteria and the need for a unified standard. Summary of the IMW consensus on response criteria and relevant outcomes S. Vincent Rajkumar, MD
10:45 am Break
11:05 am The SASS Foundation for Medical Research Award Ceremony
Francis P. Arena, MD - President & Director of Research for the SASS Foundation
Presentation: Joseph Michaeli Award for Contributions to Myeloma Research
Recipient: Philip R. Greipp, MD
11:15 am Sass Foundation/ Michaeli Award Lecture
Kinetics, proliferation, and novel agents in myeloma: Is autologous transplantation ananachronism? Philip R. Greipp, MD
11:45 am Presentation of the best Myeloma abstract
11:55 am Special lecture: Targeted therapy in myeloma Keith Stewart, M.B.Ch.B
12:20 pm Questions
12:25 pm Luncheon Symposium Session XII: Clinical cases and debates in myelomaModerator: Ruben Niesvizky, MD
2:15 pm FIRST LINE THERAPY: Clinical case of poor risk patient
Debate: Sequential therapy vs. combination therapy, triplets or more Jean-Luc Harousseau, MD (sequential)
Sagar Lonial, MD (combination)
2:45 pm CONSOLIDATION: Clinical case of good risk patient
Debate: Transplant vs. no transplant
Speaker invited (transplant)
Joan Bladé, MD (no transplant)
3:15 pm FIRST LINE THERAPY: Clinical case of non-transplant candidate
Debate:bortezomibbasedvs. IMiD based
Ruben Niesvizky, MD (bortezomib-based)
Antonio Palumbo, MD (IMiD-based)
H o te l A c co mm o da t i o n sThe Waldorf=Astoria 301 Park Avenue New York, New York 10022 Tel.: +1 (212) 355 3000 Fax: +1 (212) 872 7272 Reservation: (877) 476 8792 www.waldorf.com As one of the first “grand hotels” to combine luxurious elegance with a myriad of amenities and services, the Waldorf=Astoria has been world renowned for over a century. With a reputation for unparalleled hospitality and service, the Art Deco landmark beckons New Yorkers and visitors alike. Since1893,TheWaldorf=Astoriahasepitomizedthequintessential luxury hotel experience. Each spacious, individually decorated guest room and suite offers a rewarding union of timeless elegance and up-to-the-moment convenience, luxurious comfort and classic sophistication. The legendary shops of Fifth and Madison Avenues are only minutes away, as are numerous art galleries and specialty shops. The hotel itself is home to some of the world’s most luxurious boutiques.
For the convenience of attendees, a limited number of rooms have been reserved until September 24, 2009 at a discounted rate of $319.00 single/double occupancy, plus tax, currently at 14.25% and a $3.50 per night occupancy tax. This rate is not guaranteed outside the conference dates or after September 24, 2009.
To reserve your room please contact the Waldorf=Astoria reservations department at (877) 476 8792 or visit the hotel’s website at www.waldorf.com. To receive the group rate, callers must identify themselves as being with the Lymphoma & Myeloma 2009 group. Internet users must enter the Group/Convention Code: LYM. Reservation requests received after September 24, 2009 may not be guaranteed the group rate.
Session XIII: Relapse/ refractory disease Moderator: Roger Pearse, MD
3:45 pm SECOND LINE THERAPY: Novel combination therapies for the treatment of relapsed/ refractory multiple myeloma: Current phase I/II combinations using IMiD compounds and proteasome inhibitors as the backbone James R. Berenson, MD
4:05 pm Questions Session XIV: Special lecture Moderator: Morton Coleman, MD, FACP
4:10 pm Highlights from the 2009 International Myeloma Workshop: Are we nearing a cure inmyeloma? Sundar Jagganath, MD
4:40 pm Questions
4:50 pm Adjourn
* Please visit www.imedex.com for the most up-to-date agenda and to register.
Q u o t e s f r o m Y o u r c o l l e a g u e s :
“Lymphoma & Myeloma is the best international Congress on these subjects.”
“Outstanding level of research topics.”
“This Congress is truly comprehensive.”
“Excellent program, very informative.”
“Thank you for a great Congress – wonderful speakers!”
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the
event of cancellation. The event agenda content is subject to change without notice.
r Check if you require special facilities or assistance and attach a note with specific details and requirements.
__________________________________________________________________________________ FIRST NAME LAST NAME
DEGREE: r MD r PhD r PharmD r RN r Other Degree ____________________________________
SPECIALTY: r Hematology r Medical Oncology r Nursing r Pathology r Radiation Oncology r Surgery rOther _______________________________________________________________________ ________________________________________________________________________________________ EMAIL ADDRESS ________________________________________________________________________________________ TELEPHONE FAX ________________________________________________________________________________________ INSTITUTE DEPARTMENT ________________________________________________________________________________________ ADDRESS
________________________________________________________________________________________ CITY STATE / PROVINCE
________________________________________________________________________________________ ZIP / POSTAL CODE COUNTRY
C O N F E R E N C E R E G I S T R AT I O N
R E G I S T R AT I O N F E E S
Regular r $495 Physiciansr $345 Pharmacists* (If payment received by October 15, 2009)Full/Onsite r $595 Physiciansr $395 Pharmacists* (To register after October 15, 2009)
r $99 Nurses/Residents/Students* (*proof of eligibility must accompany registration)
Credit card transactions will appear under the name Imedex Inc. on your next statement.
To pre-register, registration and payment must be received no later than Thursday, October 15, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure that the meeting is being held as scheduled and to confirm that the meeting is not full.
For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 15, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after Thursday, October 15, 2009.
r American Express r MasterCard r Visa r Check in the amount of $______________________________
Card No. ____________________________________________ Exp. Date: _______________ /________________
Cardholder’s Name: ___________________________________ Signature: _______________________________
PAY M E N T M E T H O D
Four EASY ways to register:October 22-24, 2009 I New York, New York I The Waldorf=Astoria
A115.01
R e g i s tra t i o n To Register:You may register onlineby Thursday, October 15, 2009 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this announcement by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.
To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.
Payment: To pre-register, registration and payment must be received no later than Thursday, October 15, 2009. Please register onsite after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or check. Checks should be payable to Imedex. An attendee is not registered until full payment is received. Registration Fee Inclusions: Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the program.
Cancellation: For registration fees to be refunded, written notice of cancellation must be received at Imedex no later than Thursday, October 15, 2009. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after October 15, 2009.
Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.
The Registration and Information Desk will be staffed:
Thursday, October 22, 2009: 7:00 am – 4:30 pm
Friday, October 23, 2009: 7:30 am – 4:30 pm
Saturday, October 24, 2009: 7:30 am – 4:30 pm
R e g i s tra t i o n Fe e sRegular (Physicians) $495 ...............................................................(Pharmacists)* $345If payment received by October 15, 2009
Full/Onsite (Physicians) $595 .........................................................(Pharmacists)* $395To register after October 15, 2009
Nurses/Residents/Students* .......................................................$99*proof of eligibility must accompany registration
ONLINE. . .www.imedex.com
FAX US. . .+1 (678) 242 0920
C ALL US. . . +1 (678) 242 0906
MAIL US. . . Imedex, 4325 Alexander Dr. Alpharetta, GA, 30022-3740, USA
3 WAYS TO LEARN:
Visit www.imedex.com to learn more
LIVE meetings are produced by Imedex in 15 countries
PRINT materials are produced by Imedex for your reference needs
ONLINE products are produced by Imedex in 6 user-friendly formats
4 WAYS TO REGISTER:
4325
Ale
xan
der
Dri
veA
lph
aret
ta, G
eorg
ia 3
0022
-374
0, U
SA
Impo
rtant
Dates
Ab
stra
ct N
oti
fica
tio
ns
Mai
led
Sep
tem
ber
25,
200
9
Ab
stra
ct P
rese
nte
r R
egis
trat
ion
Dea
dlin
e O
cto
ber
8, 2
009
Reg
ula
r R
egis
trat
ion
Dea
dlin
e
Oct
ob
er 1
5, 2
009
Pre
sen
tati
on
Dat
es
Oct
ob
er 2
2-24
, 200
9
Oct
ob
er 2
2-2
4, 2
00
9 I
New
Yo
rk, N
ew Y
ork
I Th
e W
ald
orf
=A
sto
ria
Dar
k B
lue
C10
0, M
55, Y
0, K
55
Lig
ht
Blu
e C
29, M
12, Y
0, K
0
Ora
ng
e C
0, M
66, Y
100,
K0
10%
Imed
ex®
is c
om
mit
ted
to e
nvir
on
men
tal e
xcel
len
ce.
This
pu
blic
atio
n is
pri
nte
d o
n F
SC-c
erti
fied
pap
er, w
hic
h is
ac
id-f
ree,
an
d c
on
tain
s 10
% p
ost
-co
nsu
mer
recy
cled
co
nte
nt.
Imed
ex is
a b
ran
d a
nd
ass
um
ed
nam
e u
sed
by
Imed
ex, L
LC (h
ereb
y re
ferr
ed to
as
Imed
ex).
Imed
ex is
so
lely
resp
on
sib
le fo
r th
is a
gen
da’
s co
nte
nt.
Alt
ho
ug
h Im
edex
att
emp
ts
to e
nsu
re t
hat
th
e in
form
atio
n in
o
ur p
rog
ram
is a
ccu
rate
an
d t
imel
y,
mat
ters
an
d o
pin
ion
s d
iscu
ssed
an
d/
or p
rese
nte
d w
ith
resp
ect
to c
linic
al
mat
ters
are
th
ose
of t
he
dis
cuss
ion
p
arti
cip
ants
on
ly, a
nd
no
t n
eces
sari
ly
tho
se o
f Im
edex
. Mo
reov
er, a
lth
ou
gh
Im
edex
att
emp
ts to
iden
tify
an
d
inte
gra
te t
he
mo
st q
ual
ified
med
ical
p
rofe
ssio
nal
s in
ou
r pro
gra
m, T
O
THE
FULL
EST
EXTE
NT
PERM
ITTE
D
BY
LA
W, I
MED
EX E
XPR
ESSL
Y
DIS
CLA
IM A
LL W
ARR
AN
TIES
, EIT
HER
EX
PRES
S O
R IM
PLIE
D, S
TATU
TORY
O
R O
THER
WIS
E, IN
CLU
DIN
G B
UT
NO
T LI
MIT
ED T
O T
HE
IMPL
IED
W
ARR
AN
TIES
OF
MER
CH
AN
TAB
ILIT
Y,
NO
N-I
NFR
ING
EMEN
T O
F TH
IRD
PA
RTI
ES’ R
IGH
TS, A
ND
FIT
NES
S FO
R A
PA
RTI
CU
LAR
PURP
OSE
, WIT
H R
ESPE
CT
TO T
HE
CO
NTE
NT
PRES
ENTE
D.
IMED
EX F
UR
THER
MA
KES
NO
RE
PRES
ENTA
TIO
NS
OR
WA
RRA
NTI
ES
AB
OU
T TH
E A
CC
UR
AC
Y, R
ELIA
BIL
ITY,
C
OM
PLET
ENES
S O
R TI
MEL
INES
S
OF
THE
CO
NTE
NT
OR
AN
Y
MAT
ERIA
L PR
ESEN
TED
.
In a
dd
itio
n, t
he
mat
eria
l pre
sen
ted
an
d re
late
d d
iscu
ssio
ns
are
no
t in
ten
ded
to b
e m
edic
al a
dvi
ce, a
nd
th
e p
rese
nta
tio
n o
r dis
cuss
ion
of s
uch
m
ater
ial i
s n
ot
inte
nd
ed to
cre
ate
and
d
oes
no
t es
tab
lish
a p
hys
icia
n-p
atie
nt
rela
tio
nsh
ip. M
edic
al a
dvi
ce o
f an
y n
atu
re s
ho
uld
be
sou
gh
t fr
om
an
in
div
idu
al’s
ow
n p
hys
icia
n.
Nei
ther
Imed
ex n
or a
ny
of i
ts
sub
sid
iari
es o
r affi
liate
s is
affi
liate
d
wit
h o
r fo
rmal
ly e
nd
ors
ed b
y a
m
edic
al s
oci
ety.
Co
pyr
igh
t 20
09 Im
edex
®, L
LC.
All
rig
hts
rese
rved
.